Document Detail


Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats.
MedLine Citation:
PMID:  19845676     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: Hyperlipidaemia interferes with cardioprotective mechanisms, but the cause of this phenomenon is largely unknown, although hyperlipidaemia impairs the cardioprotective NO-cGMP system. However, it is not known if natriuretic peptide-cGMP-protein kinase G (PKG) signalling is affected by hyperlipidaemia. Therefore, we investigated the cardioprotective efficacy of cGMP-elevating agents in hearts from normal and hyperlipidaemic rats.
EXPERIMENTAL APPROACH: Male Wistar rats were rendered hyperlipidaemic by feeding with 2% cholesterol-enriched chow for 12 weeks. Hearts isolated from normal and hyperlipidaemic rats were perfused (Langendorff mode) and subjected to 30 min occlusion of the left main coronary artery, followed by 120 min reperfusion. 8-Br-cGMP (CG, 10 nM), B-type natriuretic peptide-32 (BNP, 10 nM), S-nitroso-N-acetyl-penicillamine (SNAP, 1 microM) were perfused from 10 min prior to coronary occlusion until the 15th min of reperfusion. Infarct size (% of ischaemic risk zone) was determined by triphenyltetrazolium staining.
KEY RESULTS: Treatment with CG, SNAP or BNP decreased infarct size significantly in normal hearts from its control value of 41.6 +/- 2.9% to 15.5 +/- 2.4%, 23.3 +/- 3.0% and 25.3 +/- 4.6%, respectively (P < 0.05). Protection by BNP was abolished by co-perfusion of PKG inhibitors KT5823 (600 nM) or Rp-8pCPT-PET-cGMPs (1 microM), confirming its PKG dependence. In hearts from hyperlipidaemic rats, CG, SNAP or BNP failed to decrease infarct size. Hyperlipidaemia did not alter basal myocardial PKG content, but decreased its activity as assessed by phosphorylation of cardiac troponin I.
CONCLUSIONS AND IMPLICATIONS: This is the first demonstration that defects in the cardioprotective cGMP-PKG system could be a critical biochemical anomaly in hyperlipidaemia.
Authors:
Z Giricz; A Görbe; J Pipis; D S Burley; P Ferdinandy; G F Baxter
Related Documents :
21860726 - Carcinoid heart disease: a rare cause of right ventricular dysfunction evaluation by tr...
1301246 - Mechanisms involved in cardiac enlargement and congestive heart failure development aft...
17053156 - A gray zone assigned to inconclusive results of quantitative diagnostic tests: applicat...
1462896 - Calcitonin gene-related peptide in patients with and without early reperfusion after ac...
3826686 - Isoflurane causes regional myocardial dysfunction in dogs with critical coronary artery...
18456206 - Catheter ablation of bundle branch reentrant ventricular tachycardia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-10-20
Journal Detail:
Title:  British journal of pharmacology     Volume:  158     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-12     Completed Date:  2010-02-25     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1495-502     Citation Subset:  IM    
Affiliation:
Department of Biochemistry, University of Szeged, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiotonic Agents / pharmacology*
Cyclic GMP / analogs & derivatives,  metabolism*,  pharmacology
Cyclic GMP-Dependent Protein Kinases / metabolism*
Dietary Fats / toxicity
Disease Models, Animal
Hyperlipidemias / complications*,  physiopathology
Male
Myocardial Infarction / etiology,  prevention & control
Myocardial Reperfusion Injury / physiopathology,  prevention & control
Natriuretic Peptide, Brain / pharmacology
Phosphorylation
Rats
Rats, Wistar
S-Nitroso-N-Acetylpenicillamine / pharmacology
Troponin I / metabolism
Grant Support
ID/Acronym/Agency:
GR074567MA//Wellcome Trust
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Dietary Fats; 0/Troponin I; 114471-18-0/Natriuretic Peptide, Brain; 31356-94-2/8-bromocyclic GMP; 7665-99-8/Cyclic GMP; 79032-48-7/S-Nitroso-N-Acetylpenicillamine; EC 2.7.11.12/Cyclic GMP-Dependent Protein Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine recep...
Next Document:  Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.